“Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)” (2019) SKIN The Journal of Cutaneous Medicine, 3, p. S39. doi:10.25251/skin.3.supp.39.